HIGHLIGHTS
- What: The study provides a strategy for deriving hypoimmunogenic CD19 CAR-NK cells from ESCs for potentially treating human B-cell malignancies. Through this experiment, the authors can better evaluate the immune compatibility of CD19 CAR-UiNK cells constructed by this strategy.
- Who: Sujith K. Joseph and colleagues from the Baylor College of Medicine, United States University of Alabama at Birmingham have published the article: Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals, in the Journal: (JOURNAL)
- How: The data . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.